UPSpace will be temporarily unavailable tonight from 19:00 to 23:00 (South African Time) due to scheduled maintenance. We apologise for any inconvenience this may cause and appreciate your understanding
 

Determinants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal : a cohort study, 2018–2021

dc.contributor.authorJohnston, Candice Leigh
dc.contributor.authorNgassa Piotie, Patrick
dc.contributor.authorMaposa, Innocent
dc.contributor.authorSingh, Sandhya
dc.contributor.authorKuonza, Lazarus R.
dc.contributor.authorDe Voux, Alex
dc.date.accessioned2024-07-31T05:53:10Z
dc.date.available2024-07-31T05:53:10Z
dc.date.issued2024-05
dc.descriptionDATA AVAILABITY STATEMENT: Permissions to publish were granted by the NDoH, the NHLS and the CCMDD Programme. The data that support the findings of this study are available from third parties, namely, the CCMDD and NHLS. Restrictions apply to the availability of these data, which were used under licence for this study. Data are available from the authors with the permission of the CCMDD and NHLS.en_US
dc.description.abstractBACKGROUND: The Central Chronic Medicines Dispensing and Distribution (CCMDD) programme facilitates clinically stable patients to collect their chronic medication from community-based pick-up points. AIM: We determined baseline glycaemic control and rates and predictors of becoming suboptimally controlled for type 2 diabetes mellitus (T2DM) CCMDD-enrolled patients. SETTING: The setting of the study was eThekwini, KwaZulu-Natal, South Africa. METHODS: We performed a cohort study (April 2018- December 2021). We linked T2DM CCMDD-enrolled patients to glycated haemoglobin (HbA1c) data from the National Health Laboratory Service. We selected patients optimally controlled at their baseline HbA1c, with ≥ 1 repeat-test available. We used Kaplan–Meier analysis to assess survival rates and extended Cox regression to determine associations between time to sub-optimal control (HbA1c > 7%) and predictors. Adjusted hazard ratios (aHRs), 95% confidence interval (CI), and p-values are reported. RESULTS: Of the 41145 T2DM patients enrolled in the CCMDD programme, 7960 (19%) had a HbA1c result available. Twenty-seven percent (2147/7960) were optimally controlled at their baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available, with 35% (242/695) changing to sub-optimal status. The HbA1c testing frequency as per national guidelines was associated with a lower hazard of sub-optimal glycaemic control (aHR: 0.46; 95% CI: 0.24–0.91; p-value = 0.024). Patients prescribed dual-therapy had a higher hazard of sub-optimal glycaemic control (aHR: 1.50; 95% CI: 1.16–1.95; p-value = 0.002) versus monotherapy. CONCLUSIONS: The HbA1c monitoring, in-line with testing frequency guidelines, is needed to alert the CCMDD programme of patients who become ineligible for enrolment. Patients receiving dual-therapy require special consideration. CONTRIBUTION: Addressing identified shortfalls can assist programme implementation.en_US
dc.description.departmentSchool of Health Systems and Public Health (SHSPH)en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sdgSDG-09: Industry, innovation and infrastructureen_US
dc.description.sponsorshipThe South African Field Epidemiology Programme.en_US
dc.description.urihttps://phcfm.org/index.php/phcfmen_US
dc.identifier.citationJohnston, L.C., Ngassa Piotie, P., Maposa, I., et al. Determinants of sub-optimal glycemic control among patients enrolledin a medicine dispensing programme in KwaZulu-Natal: A cohort study, 2018–2021. African Journal of Primary Health Care and Family Medicine 2024;16(1), a4336.https://doi.org/10.4102/phcfm.v16i1.4336.en_US
dc.identifier.issn2071-2928 (print)
dc.identifier.issn2071-2936 (online)
dc.identifier.other10.4102/phcfm.v16i1.4336
dc.identifier.urihttp://hdl.handle.net/2263/97344
dc.language.isoenen_US
dc.publisherAOSISen_US
dc.rights© 2024. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.en_US
dc.subjectCCMDD programmeen_US
dc.subjectGlucose controlen_US
dc.subjectSurvival analysisen_US
dc.subjecteThekwinien_US
dc.subjectGlycaemic controlen_US
dc.subjectCentral chronic medicines dispensing and distribution (CCMDD)en_US
dc.subjectType 2 diabetes mellitus (T2DM)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.subjectSDG-09: Industry, innovation and infrastructureen_US
dc.titleDeterminants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal : a cohort study, 2018–2021en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Johnston_Determinants_2024.pdf
Size:
718.8 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: